Show simple item record

dc.contributor.authorSchifano, Fabrizio
dc.contributor.authorChiappini, Stephania
dc.contributor.authorCorkery, John Martin
dc.contributor.authorScherbaum, Norbert
dc.contributor.authorGuirguis, Amira
dc.date.accessioned2021-04-23T23:06:54Z
dc.date.available2021-04-23T23:06:54Z
dc.date.issued2021-04-01
dc.identifier.citationSchifano , F , Chiappini , S , Corkery , J M , Scherbaum , N & Guirguis , A 2021 , ' The e-psychonaut drugs’ psychopharmacology ' , Current Opinion in Pharmacology , vol. 57 , pp. 165-174 . https://doi.org/10.1016/j.coph.2021.02.008
dc.identifier.issn1471-4892
dc.identifier.otherPURE: 24695461
dc.identifier.otherPURE UUID: 9c3426ba-2e43-4519-94ac-ae22ca129df5
dc.identifier.otherScopus: 85103392795
dc.identifier.urihttp://hdl.handle.net/2299/24307
dc.description© 2021 Elsevier Ltd. All rights reserved. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1016/j.coph.2021.02.008
dc.description.abstractThe focus here was on the pharmacological and clinical pharmacological issues pertaining to the vast range of drugs (e.g. synthetic cannabimimetics, synthetic opioids, novel stimulants, novel psychedelics, PCP/ketamine-like compounds, prescribed medicinal compounds and popular psychotropic herbs/plants) discussed by Internet-based enthusiasts of new/novel psychoactive substances (NPS), ‘e-psychonauts’. Currently ongoing related in silico studies, followed by further in vitro and in vivo/preclinical studies, will hopefully provide important findings in terms of which molecules within each given NPS class may present with higher levels of receptor affinities, and hence clinical potency. Understanding the pharmacological characteristics/potency of those novel recreational molecules will hopefully help in predicting related NPS diffusion, morbidity and possible lethality data.en
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofCurrent Opinion in Pharmacology
dc.rightsEmbargoed
dc.subjecte-psychonauts
dc.subjectpsychopharmacology
dc.subjectaddiction
dc.subjectnew psychoactive substances
dc.subjectnovel psychoactive substances
dc.subjectNPS
dc.subjectdrug abuse
dc.subjectDrug abuse
dc.subjectNovel psychoactive substances
dc.subjectAddiction
dc.subjectPsychopharmacology
dc.subjectNew psychoactive substances
dc.subjectDrug Discovery
dc.subjectPharmacology
dc.titleThe e-psychonaut drugs’ psychopharmacologyen
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.date.embargoedUntil2022-03-25
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85103392795&partnerID=8YFLogxK
dc.relation.schoolSchool of Life and Medical Sciences
dc.description.versiontypeFinal Accepted Version
dcterms.dateAccepted2021-04-01
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.coph.2021.02.008
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue
herts.rights.accesstypeEmbargoed


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record